SCHEMBL15550311

SCHEMBL15550311

CCc1nccc(C(N)=O)c1-c1nc2ccccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.46
RAB9A P51151 4/20 0.43
CHEK1 O14757 2/20 0.43
ALDH1A1 P00352 8/20 0.42
NPC1 O15118 5/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
GAA P10253 3/20 0.42
HTT P42858 2/20 0.42
MAPT P10636 2/20 0.42
RXFP1 Q9HBX9 2/20 0.42
NPSR1 Q6W5P4 4/20 0.42
HSD17B10 Q99714 3/20 0.42
PKM P14618 2/20 0.42
ABCB11 O95342 1/20 0.42
TP53 P04637 1/20 0.42
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
F7 P08709 1/20 0.41
FGFR1 P11362 2/20 0.41
FLT1 P17948 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15550990 0.81 PARP1 (0.50) KDM4ERAB9ACHEK1ALDH1A1NPC1
SCHEMBL15550309 0.81 CHEK1 (0.46) KDM4ERAB9ACHEK1ALDH1A1NPC1
SCHEMBL15552372 0.74 HPSE (0.45) KDM4ERAB9ACHEK1ALDH1A1NPC1
SCHEMBL15550756 0.73 PARP1 (0.60) KDM4ERAB9ANPC1PKMKMT2A
SCHEMBL15550994 0.73 RAB9A (0.58) KDM4ERAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL15552046 0.71 AMY1A (0.51) KDM4ERAB9ACHEK1ALDH1A1NPC1
SCHEMBL30914200 0.71 KDM4E (0.46) KDM4ERAB9ACHEK1ALDH1A1NPC1
SCHEMBL3698974 0.71 RAB9A (0.75) KDM4ERAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL30412663 0.71 RAB9A (0.75) KDM4ERAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL20797982 0.70 KDM4E (0.60) KDM4ERAB9AALDH1A1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA KDM4E 3916/4885RAB9A 1951/4885CHEK1 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.